Moreover, several clinical studies have demonstrated that the level of plasma albumin, which predominantly binds to OSI (Food and Drug Administration FDA, 2015), can influence the distribution and clearance of OSI in NSCLC patients, and have a statistically significant correlation with the efficacy of OSI in NSCLC patients (Yokota et al., 2022; Ishikawa et al., 2023). This evidence concerns the gene ALB and non-small cell lung carcinoma.